Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352131 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL17831026 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL23992348 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL20362419 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL11138374 | 0.73 | MAPT (0.62) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL11138364 | 0.73 | MAPT (0.62) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13468571 | 0.72 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL7540775 | 0.72 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL12268278 | 0.70 | — | — | |
| SCHEMBL171840 | 0.69 | MEN1 (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956303-B2 | Anti-met therapy for previously diagnosed cancer patients | GE HEALTHCARE LIMITED (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9956303-B2 | Anti-met therapy for previously diagnosed cancer patients | GE HEALTHCARE LIMITED (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9533059-B2 | Peptide radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20140335022-A1 | METHOD FOR PATIENT SELECTION | GE HEALTHCARE LIMITED (GB) | 2014-11-13 | — | — | US | disclosed |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335022-A1 | METHOD FOR PATIENT SELECTION | MET, HGF, METAP1 | SMN1; SMN2 4350/4885ALDH1A1 1623/4885KDM4E 2898/4885 |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | MET, GRPR, MEN1 | SMN1; SMN2 4412/4885ALDH1A1 4701/4885KDM4E 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.